China Slump Holds Back GSK’s International Pharma Sales
This article was originally published in PharmAsia News
GlaxoSmithKline has joined the ranks of other multinational pharma firms including Lilly and Novartis that have seen a slump in their China business in the second quarter. A global restructuring program as well as some capacity constraints also affected the quarterly international sales of the British firm's global pharma business.
You may also be interested in...
US FDA defers action on Spectrum’s approval application for neutropenia candidate Rolontis due to pandemic-related difficulties inspecting partner Hanmi’s plant. The action date has been put back by around four months although the companies stress no CRL has been issued.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.